NCT04885855

8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

Efficacy and Safety of 8- Versus 12-week Sofosbuvir-ravidasvir Treatment of Non-cirrhotic Chronic Hepatitis C Patients: An Open-label, Randomized, Multicenter Study in Malaysia

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 322 (actual)
• Sponsor: Muhammad Radzi Abu Hassan · Other Government
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is open-label, randomized, multicentre study to compare the efficacy and safety of the 8-week versus 12-week of SOF-RVD combination treatment for non-cirrhotic chronic hepatitis C patients. All the recruited subjects will receive the treatment accordingly and be followed up for 24 weeks following the completion of treatment.

Conditions

• Hepatitis C

Interventions

Type	Name	Description
DRUG	Sofosbuvir 400 MG	Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)
DRUG	Ravidasvir 200mg	Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)

Timeline

• Start date: 2021-03-23
• Primary completion: 2023-12-29
• Completion: 2024-03-15
• First posted: 2021-05-13
• Last updated: 2025-03-13

Locations

1 site across 1 country: Malaysia